Dennis Paustenbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dennis Paustenbach has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Michael E. Stevens
TRC Strategic Health Sciences
7 shared publications - Blake Deckard
TRC Strategic Health Sciences Division
5 shared publications - Quincy Perry
TRC Strategic Health Sciences
5 shared publications - David W. Brew
Paustenbach and Associates
4 shared publications - Jacob Siracusa
TRC Strategic Health Sciences
4 shared publications - Karmen Kissell
TRC Strategic Health Sciences Division
3 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Taylor & Francis in Journal of the Air & Waste Management Association
- Vol. 76 (11) , 903-907
Response to the comment on Perry et al. 2026. A risk assessment of ethylene oxide release from a sterilization facility into a community. Journal of the Air & Waste Management Association
- 2 November 2026
- Published by Taylor & Francis in Journal of the Air & Waste Management Association
- Vol. 76 (11) , 903-907
Open AccessResponse to the comment on Perry et al. 2026. A risk assessment of ethylene oxide release from a sterilization facility into a community. Journal of the Air & Waste Management Association
- Open Access
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1107-1116
Retraction of the landmark glyphosate safety publication by Williams, Kroes and Munro (2000) should be reversed
The decision by the co-Editor-in-Chief of Regulatory Toxicology and Pharmacology, Prof. Martin van den Berg, to retract the 2000 review article by Williams, Kroes, and Munro has elicited widespread criticism within the scientific community. Issued in late 2025, the retraction decision cites procedural concerns including potential ghostwriting, undisclosed conflicts of interest, and omission of certain unpublished studies, invoking Committee on Publication Ethics guidelines despite lacking evidence of fraud or scientific flaws. This editorial argues that the retraction decision involves editorial overreach and misapplication of the guidelines. The alleged omissions stemmed from proprietary data access limitations that were disclosed in the original paper. Subsequent reviews by several independent expert panels and regulatory authorities with access to all glyphosate data, including the studies cited by the retracting editor, reached similar conclusions. Claims of ghostwriting were previously investigated and found lacking, including a declaration by EFSA as to the clarity of the conflict disclosures. The retraction’s timing, reliance on litigation documents, and apparent biases that were not disclosed in the retraction notice raise questions of ideological interference. Absent substantive rebuttals based on scientific merit rather than speculative claims of inappropriate authorship and data access, this retraction decision sets a dangerous precedent for retroactive censorship, potentially chilling beneficial industry-academic collaborations and eroding trust in the integrity of scientific publishing. With the strongest conviction, we assert that retracting a paper without scientific flaws isn’t protection—it is censorship. We therefore call for the immediate reversal of this flawed and unjustified retraction to preserve trust in peer-reviewed literature.
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1107-1116
Open AccessRetraction of the landmark glyphosate safety publication by Williams, Kroes and Munro (2000) should be reversed
The decision by the co-Editor-in-Chief of Regulatory Toxicology and Pharmacology, Prof. Martin van den Berg, to retract the 2000 review article by Williams, Kroes, and Munro has elicited widespread criticism within the scientific community. Issued in late 2025, the retraction decision cites procedural concerns including potential ghostwriting, undisclosed conflicts of interest, and omission of certain unpublished studies, invoking Committee on Publication Ethics guidelines despite lacking evidence of fraud or scientific flaws. This editorial argues that the retraction decision involves editorial overreach and misapplication of the guidelines. The alleged omissions stemmed from proprietary data access limitations that were disclosed in the original paper. Subsequent reviews by several independent expert panels and regulatory authorities with access to all glyphosate data, including the studies cited by the retracting editor, reached similar conclusions. Claims of ghostwriting were previously investigated and found lacking, including a declaration by EFSA as to the clarity of the conflict disclosures. The retraction’s timing, reliance on litigation documents, and apparent biases that were not disclosed in the retraction notice raise questions of ideological interference. Absent substantive rebuttals based on scientific merit rather than speculative claims of inappropriate authorship and data access, this retraction decision sets a dangerous precedent for retroactive censorship, potentially chilling beneficial industry-academic collaborations and eroding trust in the integrity of scientific publishing. With the strongest conviction, we assert that retracting a paper without scientific flaws isn’t protection—it is censorship. We therefore call for the immediate reversal of this flawed and unjustified retraction to preserve trust in peer-reviewed literature.
- Open Access
- 14 April 2026
- Published by Taylor & Francis in Journal of the Air & Waste Management Association
- Vol. 76 (8) , 646-666
A risk assessment of ethylene oxide release from a sterilization facility into a community
In recent decades, ethylene oxide (EtO) has been a widely used industrial sterilant and chemical intermediate that has faced increasing scrutiny related to its carcinogenic potential. This study evaluated residential and occupational exposure to EtO in a valley surrounding two point-source emissions in close proximity (~11 meters apart). Air samples were collected in residential and industrial areas. Eight locations, ranging from 100 to 1700 meters from the center of the point-sources in varying directions, had average concentrations between 0.290 and 3.212 µg/m3 (0.16 to 1.8 ppb) with peak levels reaching 26.4 µg/m3 (15 ppb). Exposure scenarios were developed based on daily activity patterns, long-term residency, and estimates derived from historical emissions data. Under the most conservative assumptions, including 40 years of occupational exposure during the periods of highest recorded emissions around the facility, the maximum estimated cumulative lifetime exposure was 591 ppm-days. When compared with epidemiology studies of EtO-exposed workers from similar facilities (studies used by the EPA and IARC in their cancer risk assessments), the highest cumulative exposures observed (13,500+ ppm-days) were at least 23-fold higher than our maximum estimated lifetime exposure value (591 ppm-days). Importantly, these high-exposure groups showed no statistically significant cancer incidence, particularly for breast and lymphohematopoietic cancers. When compared to regulatory values and health-based benchmarks adjusted to cumulative exposures, estimated exposures were substantially below levels associated with increased cancer incidence in epidemiological cohorts for the community surrounding the sterilization facility, even to the most susceptible populations.Implications: This study provides a data-driven, site-specific framework for evaluating long-term human health risks from ethylene oxide (EtO) emissions, using ambient air monitoring, historical emissions data, and conservative EPA-aligned exposure assumptions. Despite assessing one of the highest-emitting sterilization facilities in the U.S. estimated exposures remained well below levels linked to increased cancer risk in epidemiological studies. These findings challenge the assumption that facility proximity alone poses significant health risk and support the development of risk-based, proportionate air quality policies. The approach offers regulatory agencies a more transparent and scientifically grounded basis for EtO risk characterization under the Clean Air Act, TSCA, and state air toxics programs.
- 14 April 2026
- Published by Taylor & Francis in Journal of the Air & Waste Management Association
- Vol. 76 (8) , 646-666
Open AccessA risk assessment of ethylene oxide release from a sterilization facility into a community
In recent decades, ethylene oxide (EtO) has been a widely used industrial sterilant and chemical intermediate that has faced increasing scrutiny related to its carcinogenic potential. This study evaluated residential and occupational exposure to EtO in a valley surrounding two point-source emissions in close proximity (~11 meters apart). Air samples were collected in residential and industrial areas. Eight locations, ranging from 100 to 1700 meters from the center of the point-sources in varying directions, had average concentrations between 0.290 and 3.212 µg/m3 (0.16 to 1.8 ppb) with peak levels reaching 26.4 µg/m3 (15 ppb). Exposure scenarios were developed based on daily activity patterns, long-term residency, and estimates derived from historical emissions data. Under the most conservative assumptions, including 40 years of occupational exposure during the periods of highest recorded emissions around the facility, the maximum estimated cumulative lifetime exposure was 591 ppm-days. When compared with epidemiology studies of EtO-exposed workers from similar facilities (studies used by the EPA and IARC in their cancer risk assessments), the highest cumulative exposures observed (13,500+ ppm-days) were at least 23-fold higher than our maximum estimated lifetime exposure value (591 ppm-days). Importantly, these high-exposure groups showed no statistically significant cancer incidence, particularly for breast and lymphohematopoietic cancers. When compared to regulatory values and health-based benchmarks adjusted to cumulative exposures, estimated exposures were substantially below levels associated with increased cancer incidence in epidemiological cohorts for the community surrounding the sterilization facility, even to the most susceptible populations.Implications: This study provides a data-driven, site-specific framework for evaluating long-term human health risks from ethylene oxide (EtO) emissions, using ambient air monitoring, historical emissions data, and conservative EPA-aligned exposure assumptions. Despite assessing one of the highest-emitting sterilization facilities in the U.S. estimated exposures remained well below levels linked to increased cancer risk in epidemiological studies. These findings challenge the assumption that facility proximity alone poses significant health risk and support the development of risk-based, proportionate air quality policies. The approach offers regulatory agencies a more transparent and scientifically grounded basis for EtO risk characterization under the Clean Air Act, TSCA, and state air toxics programs.
- Open Access
- 16 March 2026
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 56 (3) , 176-203
The formaldehyde dispute – Part B: scientific critique of EPA’s formaldehyde occupational exposure values (OEVs) and proposed alternative occupational exposure limits (OELs)
- 16 March 2026
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 56 (3) , 176-203
Open AccessThe formaldehyde dispute – Part B: scientific critique of EPA’s formaldehyde occupational exposure values (OEVs) and proposed alternative occupational exposure limits (OELs)
- Open Access
- 16 March 2026
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 56 (3) , 157-175
The formaldehyde dispute - Part A: acute and chronic inhalation toxicity and the evolution of scientific knowledge
- 16 March 2026
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 56 (3) , 157-175
Open AccessThe formaldehyde dispute - Part A: acute and chronic inhalation toxicity and the evolution of scientific knowledge
- 1 January 2026
- Published by International Society of Regulatory Toxicology and Pharmacology in Journal of Toxicology and Regulatory Policy
- Vol. 2 (1) , 1-22
Quantitative assessment of indoor asbestos fiber resuspension: comparing theoretical predictions to empirical data
Summary: For over six decades, regulatory agencies have asserted that asbestos is readily resuspended by indoor activities such as walking and sweeping. Numerous aerosol physicists have challenged this claim, arguing that, based on fundamental particle adhesion theory, resuspension is unlikely, particularly for biologically relevant fibers. To empirically evaluate this discrepancy between theoretical predictions and practical observations, chrysotile fibers were uniformly distributed on an epoxy-coated concrete floor. A volunteer performed two representative disturbance scenarios: walking and sweeping, conducted on a 3 × 3-m test area. Fiber surface loadings were measured to be 2.9 × 10 11 and 2.6 × 10 11 fibers for the walking and sweeping trials, respectively. Airborne fibers were sampled and characterized across a spectrum of widths and lengths, including fibers as short as 0.5 μm and up to 74 μm, with a range of aspect ratios. Particular attention was given to OSHA-classified fibers (≥5 μm in length: ≥3:1 aspect ratio). The resuspension efficiency of these fibers was found to be exceedingly low under both disturbance conditions. Despite the presence of nearly 300 billion fibers on the surface, about 0.0001% were resuspended. Resuspended fibers were further grouped by size class, and results were interpreted considering aerosol theoretical models emphasizing the role of surface area-to-volume (SA-V) ratio in fiber adhesion and detachment dynamics. These findings are consistent with longstanding aerosol science predictions that emphasize the strong adhesion of elongated, high SA-V fibers to flat indoor surfaces. Notably, while previous studies, including those conducted after the World Trade Center collapsed, have observed similar behavior, their implications have not been integrated into policy or exposure modeling. This appears to be the first study to quantitatively confirm the relationship between fiber morphology and resuspension potential. It also puts into question the hundreds of claims of the past twenty years of litigation alleging asbestos-related disease with take home exposure.
- 1 January 2026
- Published by International Society of Regulatory Toxicology and Pharmacology in Journal of Toxicology and Regulatory Policy
- Vol. 2 (1) , 1-22
Quantitative assessment of indoor asbestos fiber resuspension: comparing theoretical predictions to empirical data
Summary: For over six decades, regulatory agencies have asserted that asbestos is readily resuspended by indoor activities such as walking and sweeping. Numerous aerosol physicists have challenged this claim, arguing that, based on fundamental particle adhesion theory, resuspension is unlikely, particularly for biologically relevant fibers. To empirically evaluate this discrepancy between theoretical predictions and practical observations, chrysotile fibers were uniformly distributed on an epoxy-coated concrete floor. A volunteer performed two representative disturbance scenarios: walking and sweeping, conducted on a 3 × 3-m test area. Fiber surface loadings were measured to be 2.9 × 10 11 and 2.6 × 10 11 fibers for the walking and sweeping trials, respectively. Airborne fibers were sampled and characterized across a spectrum of widths and lengths, including fibers as short as 0.5 μm and up to 74 μm, with a range of aspect ratios. Particular attention was given to OSHA-classified fibers (≥5 μm in length: ≥3:1 aspect ratio). The resuspension efficiency of these fibers was found to be exceedingly low under both disturbance conditions. Despite the presence of nearly 300 billion fibers on the surface, about 0.0001% were resuspended. Resuspended fibers were further grouped by size class, and results were interpreted considering aerosol theoretical models emphasizing the role of surface area-to-volume (SA-V) ratio in fiber adhesion and detachment dynamics. These findings are consistent with longstanding aerosol science predictions that emphasize the strong adhesion of elongated, high SA-V fibers to flat indoor surfaces. Notably, while previous studies, including those conducted after the World Trade Center collapsed, have observed similar behavior, their implications have not been integrated into policy or exposure modeling. This appears to be the first study to quantitatively confirm the relationship between fiber morphology and resuspension potential. It also puts into question the hundreds of claims of the past twenty years of litigation alleging asbestos-related disease with take home exposure.
- Open Access
- 26 November 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (10) , 982-994
Risk assessment of trace hydrazine in a 2020 bottled water-associated nonviral hepatitis outbreak
Between August 1 and December 3, 2020, a 124-day outbreak of nonviral hepatitis occurred in geographically limited regions of Nevada and California, resulting in 21 hospitalized cases (18 in Nevada, 3 in California), including 18 intensive care unit admissions and one fatality in an adult female with preexisting conditions. In March 2021, a multi-agency investigation led by the Southern Nevada Health District (SNHD), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), and others identified consumption of Real Water, an alkalinized bottled water product, as the likely cause. On March 24, 2021, a recall was issued and the company ceased production of Real Water. Despite extensive investigation, no definitive causative agent was identified. However, trace concentrations of hydrazine, a known hepatotoxin, were detected in select product batches, prompting concerns regarding its potential role in the outbreak. This study presents a quantitative risk assessment of hydrazine exposure from daily consumption of retail bottled Real Water products during the outbreak period. Estimated intake was calculated based on age-, sex-, and body weight-specific water consumption patterns and measured hydrazine concentrations (mean: 0.0505 mg/L; maximum: 0.3 mg/L). Sub-chronic acceptable daily intakes (ADIs) of 0.09 mg/kg-day for adults and 0.04 mg/kg-day for children were developed based on toxicological data from isoniazid (INH) studies. Hydrazine and INH share similar profiles regarding hepatotoxicity, with hydrazine acting as a major mediator of INH-induced liver injury. Calculated hazard quotients for all demographic groups were via retail Real Water consumption could not have caused the observed hepatic injuries, supporting the conclusion of the Centers for Disease Control (CDC) that the etiologic agent remains unidentified.
- 26 November 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (10) , 982-994
Open AccessRisk assessment of trace hydrazine in a 2020 bottled water-associated nonviral hepatitis outbreak
Between August 1 and December 3, 2020, a 124-day outbreak of nonviral hepatitis occurred in geographically limited regions of Nevada and California, resulting in 21 hospitalized cases (18 in Nevada, 3 in California), including 18 intensive care unit admissions and one fatality in an adult female with preexisting conditions. In March 2021, a multi-agency investigation led by the Southern Nevada Health District (SNHD), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), and others identified consumption of Real Water, an alkalinized bottled water product, as the likely cause. On March 24, 2021, a recall was issued and the company ceased production of Real Water. Despite extensive investigation, no definitive causative agent was identified. However, trace concentrations of hydrazine, a known hepatotoxin, were detected in select product batches, prompting concerns regarding its potential role in the outbreak. This study presents a quantitative risk assessment of hydrazine exposure from daily consumption of retail bottled Real Water products during the outbreak period. Estimated intake was calculated based on age-, sex-, and body weight-specific water consumption patterns and measured hydrazine concentrations (mean: 0.0505 mg/L; maximum: 0.3 mg/L). Sub-chronic acceptable daily intakes (ADIs) of 0.09 mg/kg-day for adults and 0.04 mg/kg-day for children were developed based on toxicological data from isoniazid (INH) studies. Hydrazine and INH share similar profiles regarding hepatotoxicity, with hydrazine acting as a major mediator of INH-induced liver injury. Calculated hazard quotients for all demographic groups were via retail Real Water consumption could not have caused the observed hepatic injuries, supporting the conclusion of the Centers for Disease Control (CDC) that the etiologic agent remains unidentified.
- Open Access
- 21 October 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (9) , 809-866
A comparative toxicological and epidemiological evaluation of dioxins and PFAS chemicals
Regulatory frameworks, informed by robust and transparent scientific evidence, can significantly benefit society when thoughtful and measured regulation is promulgated. However, regulations founded on incomplete or misinterpreted science often result in unintended consequences. As was the case with the polychlorinated dibenzodioxin and polychlorinated dibenzofuran (PCDD/PCDF) chemicals, for the past 50 years, there has been a lack of scientific consensus on the adverse health effects of per- and polyfluoroalkyl substances (PFAS) in humans at current blood concentrations (about 4 ppb TEQ) or even concentrations 10-300-fold higher (40-1200 ppb TEQ). Despite their distinctly different chemical structures, the dioxins, particularly 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and perfluorooctanoic acid (PFOA)/perfluorooctanesulfonic acid (PFOS), share notable similarities: environmental persistence, biological recalcitrance, slightly unpredictable acute toxicity, a lack of genotoxicity, and suggestive data on adverse health effects in humans; across a wide range of doses. Both substances display varying degrees of acute toxicity across species, and both have been associated with the onset of wasting syndrome in certain animals at fairly high doses, but wasting syndrome is not seen in humans. Although there is moderate to high acute toxicity in multiple animal species for both families of chemicals, there is low acute toxicity in humans. In humans, both compounds interact with fatty acid metabolism. The evidence indicates that both are either weakly genotoxic or non-genotoxic. The dioxins can cause cancer in a variety of animal species, but even in humans exposed to high doses, no increased cancer risk is apparent. PFAS chemicals are similar; weakly carcinogenic in animals and, perhaps, lacking carcinogenic potency in humans. However, unlike with dioxins, high human exposure to PFAS has only occurred in the workplace; thus, few data from highly exposed human populations are available to rigorously evaluate the human cancer risk or other potential effects at elevated doses. Similar to the widespread presence of dioxins reported in the 1970s-1980s, PFAS chemicals are now globally ubiquitous, with detectable concentrations in nearly every individual, fish, and wildlife species. As awareness has increased over time, pressure to prevent the release or manufacture of PFOA and PFOS has decreased the blood concentrations in Americans by 10-fold over the past 15 years, paralleling trends observed with the dioxins when global concerns surfaced. The dioxins were regulated in a heavy-handed manner despite scientific uncertainty regarding their human health risks over a range of exposure levels, as well as a lack of consensus on dose-response relationships, thresholds for adverse effects, and human relevance of high-dose animal studies. The regulatory actions that occurred with the dioxins ultimately resulted in substantial economic and societal costs, even in the face of much uncertainty. This paper examines the parallels between the development of scientific understanding of the health hazards and the eventual regulation of dioxins and PFAS chemicals. For both families of chemicals, the precautionary principle was followed by most agencies rather than solid scientific data during the rulemaking process.
- 21 October 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (9) , 809-866
Open AccessA comparative toxicological and epidemiological evaluation of dioxins and PFAS chemicals
Regulatory frameworks, informed by robust and transparent scientific evidence, can significantly benefit society when thoughtful and measured regulation is promulgated. However, regulations founded on incomplete or misinterpreted science often result in unintended consequences. As was the case with the polychlorinated dibenzodioxin and polychlorinated dibenzofuran (PCDD/PCDF) chemicals, for the past 50 years, there has been a lack of scientific consensus on the adverse health effects of per- and polyfluoroalkyl substances (PFAS) in humans at current blood concentrations (about 4 ppb TEQ) or even concentrations 10-300-fold higher (40-1200 ppb TEQ). Despite their distinctly different chemical structures, the dioxins, particularly 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and perfluorooctanoic acid (PFOA)/perfluorooctanesulfonic acid (PFOS), share notable similarities: environmental persistence, biological recalcitrance, slightly unpredictable acute toxicity, a lack of genotoxicity, and suggestive data on adverse health effects in humans; across a wide range of doses. Both substances display varying degrees of acute toxicity across species, and both have been associated with the onset of wasting syndrome in certain animals at fairly high doses, but wasting syndrome is not seen in humans. Although there is moderate to high acute toxicity in multiple animal species for both families of chemicals, there is low acute toxicity in humans. In humans, both compounds interact with fatty acid metabolism. The evidence indicates that both are either weakly genotoxic or non-genotoxic. The dioxins can cause cancer in a variety of animal species, but even in humans exposed to high doses, no increased cancer risk is apparent. PFAS chemicals are similar; weakly carcinogenic in animals and, perhaps, lacking carcinogenic potency in humans. However, unlike with dioxins, high human exposure to PFAS has only occurred in the workplace; thus, few data from highly exposed human populations are available to rigorously evaluate the human cancer risk or other potential effects at elevated doses. Similar to the widespread presence of dioxins reported in the 1970s-1980s, PFAS chemicals are now globally ubiquitous, with detectable concentrations in nearly every individual, fish, and wildlife species. As awareness has increased over time, pressure to prevent the release or manufacture of PFOA and PFOS has decreased the blood concentrations in Americans by 10-fold over the past 15 years, paralleling trends observed with the dioxins when global concerns surfaced. The dioxins were regulated in a heavy-handed manner despite scientific uncertainty regarding their human health risks over a range of exposure levels, as well as a lack of consensus on dose-response relationships, thresholds for adverse effects, and human relevance of high-dose animal studies. The regulatory actions that occurred with the dioxins ultimately resulted in substantial economic and societal costs, even in the face of much uncertainty. This paper examines the parallels between the development of scientific understanding of the health hazards and the eventual regulation of dioxins and PFAS chemicals. For both families of chemicals, the precautionary principle was followed by most agencies rather than solid scientific data during the rulemaking process.
- Open Access
- 16 March 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (3) , 368-415
United States Environmental Protection Agency's Perfluorooctanoic Acid, Perfluorooctane Sulfonic Acid, and Related Per- and Polyfluoroalkyl Substances 2024 Drinking Water Maximum Contaminant Level: Part 2 – Fifteen Misconceptions About the Health Hazards
This paper examines widely held beliefs about the six per- and polyfluoroalkyl substances (PFAS) addressed in the final U.S. Environmental Protection Agency's (EPA) rule on PFAS in drinking water (e.g., the Maximum Contaminant Levels - MCLs). Based on our understanding of the scientific literature and the comments submitted by stakeholders regarding the EPA's regulation that was promulgated in April 2024, we identified 15 misconceptions that had a weak scientific foundation. These are now memoralized in the MCLs for the six PFAS but remain debated due to ongoing ambiguous research findings. Many critics of the MCLs found the EPA's systematic review of the published relevant information, particularly the toxicology of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS), to be inadequate. The following seven views are among the most important. First, the EPA asserted that the toxicology of these six chemicals was poorly understood and lacked sufficient data to determine a safe daily intake level for chronic health effects; nonetheless, they promulgated what may be the costliest environmental regulation to date. Notably, adverse effects remain difficult to demonstrate in occupationally exposed individuals even at blood concentrations 50-100 times higher than current background PFAS levels. Second, the Agency indicated that the epidemiology data showed that exposure to PFOA and PFOS caused kidney and potentially other cancers, yet the data were equivocal and do not support that assertion. Third, it was stated that specific non-cancer effects, such as heart disease, would be prevented under the promulgated rule; however, the studies that they relied upon do not show an increased incidence of heart disease even in highly exposed populations. Fourth, the Agency relied on animal data to support its views on the likely toxic effects in humans, despite ample toxicology data that animals, particularly rodents, are poor predictors of the human response to PFAS exposures. Fifth, the EPA predicted a reduction in healthcare expenditures that would offset much of the cost of complying with the MCL, but, they did not have adequate data to support this prediction. Sixth, the EPA suggested that these six PFAS act through a shared mechanism of action (i.e., PPARα pathway induction); however, data indicate that PPARα induction in humans may be 80% less than what is observed in rodents. Also, induction of the PPARα pathway is not a cause of systemic disease. Seventh, the Agency failed to disclose that achieving the new MCL would yield negligible reductions in blood PFAS levels even among highly exposed populations, given drinking water accounts for only 20% or less of total PFAS exposure. The survey that could answer that question, the EPA's fifth Unregulated Contaminant Monitoring Rule, was only 25% complete at the time the MCL was promulgated. Overall, our analysis concluded that while the EPA's intent to regulate these chemicals due to their environmental presence was necessary, the derivation of the MCLs and the alleged health effects was based on the application of the precautionary principle rather than robust scientific evidence.
- 16 March 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (3) , 368-415
Open AccessUnited States Environmental Protection Agency's Perfluorooctanoic Acid, Perfluorooctane Sulfonic Acid, and Related Per- and Polyfluoroalkyl Substances 2024 Drinking Water Maximum Contaminant Level: Part 2 – Fifteen Misconceptions About the Health Hazards
This paper examines widely held beliefs about the six per- and polyfluoroalkyl substances (PFAS) addressed in the final U.S. Environmental Protection Agency's (EPA) rule on PFAS in drinking water (e.g., the Maximum Contaminant Levels - MCLs). Based on our understanding of the scientific literature and the comments submitted by stakeholders regarding the EPA's regulation that was promulgated in April 2024, we identified 15 misconceptions that had a weak scientific foundation. These are now memoralized in the MCLs for the six PFAS but remain debated due to ongoing ambiguous research findings. Many critics of the MCLs found the EPA's systematic review of the published relevant information, particularly the toxicology of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS), to be inadequate. The following seven views are among the most important. First, the EPA asserted that the toxicology of these six chemicals was poorly understood and lacked sufficient data to determine a safe daily intake level for chronic health effects; nonetheless, they promulgated what may be the costliest environmental regulation to date. Notably, adverse effects remain difficult to demonstrate in occupationally exposed individuals even at blood concentrations 50-100 times higher than current background PFAS levels. Second, the Agency indicated that the epidemiology data showed that exposure to PFOA and PFOS caused kidney and potentially other cancers, yet the data were equivocal and do not support that assertion. Third, it was stated that specific non-cancer effects, such as heart disease, would be prevented under the promulgated rule; however, the studies that they relied upon do not show an increased incidence of heart disease even in highly exposed populations. Fourth, the Agency relied on animal data to support its views on the likely toxic effects in humans, despite ample toxicology data that animals, particularly rodents, are poor predictors of the human response to PFAS exposures. Fifth, the EPA predicted a reduction in healthcare expenditures that would offset much of the cost of complying with the MCL, but, they did not have adequate data to support this prediction. Sixth, the EPA suggested that these six PFAS act through a shared mechanism of action (i.e., PPARα pathway induction); however, data indicate that PPARα induction in humans may be 80% less than what is observed in rodents. Also, induction of the PPARα pathway is not a cause of systemic disease. Seventh, the Agency failed to disclose that achieving the new MCL would yield negligible reductions in blood PFAS levels even among highly exposed populations, given drinking water accounts for only 20% or less of total PFAS exposure. The survey that could answer that question, the EPA's fifth Unregulated Contaminant Monitoring Rule, was only 25% complete at the time the MCL was promulgated. Overall, our analysis concluded that while the EPA's intent to regulate these chemicals due to their environmental presence was necessary, the derivation of the MCLs and the alleged health effects was based on the application of the precautionary principle rather than robust scientific evidence.
- Top Cited PapersOpen Access
- 16 March 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (3) , 321-367
United States Environmental Protection Agency's Perfluorooctanoic Acid, Perfluorooctane Sulfonic Acid, and Related Per- and Polyfluoroalkyl Substances 2024 Drinking Water Maximum Contaminant Level: Part 1 – Analysis of Public Comments
In March 2023, the EPA proposed a 4.0 ppt maximum contaminant level (MCL) for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) (each) and a hazard index approach for four other PFAS. The EPA sought public feedback on the proposed MCL in early 2023 and received 1626 comment submissions via the PFAS docket website (Docket ID: EPA-HQ-OW-2022-0114). Final MCLs were promulgated on April 10, 2024. Our analysis of the PFAS docket identified 128 comments that had a reasonable degree of scientific merit, with 57 comments endorsing the regulations and 71 questioning the MCLs public health utility. Critics noted the lack of evidence for adverse health effects at low PFAS exposures, the rule's significant impact on the economy, and the EPA's selection of published papers which the Agency chose to support their views. Many well-substantiated comments highlighted that few, if any, adverse health effects were reported at doses as much as 100-1000 times above those associated with the proposed drinking water guidelines. We found that the comments which discussed the evidence linking PFAS exposures below 200 ppt in drinking water to adverse health effects were equivocal. Most of the well-documented science based comments indicated that the data did not justify setting a 4.0 ppt MCL. It was noted that the EPA MCL was quite different from drinking water standards in other countries (up to 8-140 fold lower). During the review, it became apparent that a 4.0 ppt MCL may have little effect on PFAS blood concentrations in most Americans since drinking water accounts for less than 20% of their total PFAS intake. Additionally, a significant portion of the American population consumes minimal amounts of tap water. Commenters noted that the financial burden for treatment and cleanup was much higher than what was reported in the justification for the final MCL which was submitted to the Office of Management and Budget (OMB) and eventually promulgated. It is possible that EPA underestimated the financial impact on the nation by up to 100 to 200-fold. Our analysis indicates that many, if not most, of the scientifically rigorous comments on the EPA's proposed MCL were not acknowledged or considered by the Agency. We conclude the article by offering sixteen recommendations for the EPA to consider if Congress or the courts choose to reopen the evaluation of these MCLs. These included convening an international expert panel, reevaluating the appropriateness of the LNT model for PFAS, ensuring adequate time for study quality assessment and cost-benefit analysis, considering an approach to implementing a series of MCLs, critically reevaluating scientific studies, adhering to EPA risk assessment guidelines, addressing SDWA compliance concerns, revisiting the Hazard Index approach, and ensuring thorough and transparent review of public comments.
- 16 March 2025
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 55 (3) , 321-367
Top Cited PapersOpen AccessUnited States Environmental Protection Agency's Perfluorooctanoic Acid, Perfluorooctane Sulfonic Acid, and Related Per- and Polyfluoroalkyl Substances 2024 Drinking Water Maximum Contaminant Level: Part 1 – Analysis of Public Comments
In March 2023, the EPA proposed a 4.0 ppt maximum contaminant level (MCL) for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) (each) and a hazard index approach for four other PFAS. The EPA sought public feedback on the proposed MCL in early 2023 and received 1626 comment submissions via the PFAS docket website (Docket ID: EPA-HQ-OW-2022-0114). Final MCLs were promulgated on April 10, 2024. Our analysis of the PFAS docket identified 128 comments that had a reasonable degree of scientific merit, with 57 comments endorsing the regulations and 71 questioning the MCLs public health utility. Critics noted the lack of evidence for adverse health effects at low PFAS exposures, the rule's significant impact on the economy, and the EPA's selection of published papers which the Agency chose to support their views. Many well-substantiated comments highlighted that few, if any, adverse health effects were reported at doses as much as 100-1000 times above those associated with the proposed drinking water guidelines. We found that the comments which discussed the evidence linking PFAS exposures below 200 ppt in drinking water to adverse health effects were equivocal. Most of the well-documented science based comments indicated that the data did not justify setting a 4.0 ppt MCL. It was noted that the EPA MCL was quite different from drinking water standards in other countries (up to 8-140 fold lower). During the review, it became apparent that a 4.0 ppt MCL may have little effect on PFAS blood concentrations in most Americans since drinking water accounts for less than 20% of their total PFAS intake. Additionally, a significant portion of the American population consumes minimal amounts of tap water. Commenters noted that the financial burden for treatment and cleanup was much higher than what was reported in the justification for the final MCL which was submitted to the Office of Management and Budget (OMB) and eventually promulgated. It is possible that EPA underestimated the financial impact on the nation by up to 100 to 200-fold. Our analysis indicates that many, if not most, of the scientifically rigorous comments on the EPA's proposed MCL were not acknowledged or considered by the Agency. We conclude the article by offering sixteen recommendations for the EPA to consider if Congress or the courts choose to reopen the evaluation of these MCLs. These included convening an international expert panel, reevaluating the appropriateness of the LNT model for PFAS, ensuring adequate time for study quality assessment and cost-benefit analysis, considering an approach to implementing a series of MCLs, critically reevaluating scientific studies, adhering to EPA risk assessment guidelines, addressing SDWA compliance concerns, revisiting the Hazard Index approach, and ensuring thorough and transparent review of public comments.